Janus kinase inhibitors (JAKis) have transformed the landscape of dermatological therapy over the last 2 years, with six United States Food and Drug Administration approvals and further clinical trials in progress.1 JAKis have proven highly efficacious in dermatological diseases, by blocking the JAK-signal transducer and activator of transcription (STAT) signalling pathway involved in numerous inflammatory […]

Chronic spontaneous urticaria (CSU), a common and distressing skin condition driven by mast cells, is typically managed with a stepwise approach using second-generation H1-antihistamines, omalizumab and cyclosporine, as recommended by international guidelines. However, many patients with CSU do not respond optimally to this standardized treatment, likely due to the diverse underlying mechanisms involved. As a […]

The pathogenesis of cutaneous granulomatous disorders is incompletely understood and many unmet needs remain in the treatment paradigm.1 These disorders can be categorized into two main groups: those caused by infections and those associated with inflammatory skin conditions, among the most prevalent inflammatory disorders are granuloma annulare (GA) and cutaneous sarcoidosis (CS).1 The presentation of […]